Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
murine BCMA-CART
- Development stage
- Unknown
- Lead developer
- Hospital Clínic de Barcelona
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
murine BCMA-CART (also known as ARI2m) is a chimeric antigen receptor T-cell (CAR-T) therapy engineered to target B-cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells in multiple myeloma. The extracellular antigen-recognition domain of this CAR is derived from a murine (mouse) single-chain variable fragment specific for human BCMA. Upon infusion into the patient, these genetically modified autologous T cells recognize and kill BCMA-expressing tumor cells through cytotoxic immune mechanisms. Preclinical studies demonstrated efficacy against multiple myeloma; however, the use of a non-human (murine) scFv can lead to immunogenicity and potential immune rejection by patients[1][3]. This has led to the development of humanized versions with improved safety and efficacy profiles.
- Other names
- ARI2mARI-2mARI 2mmurine anti-BCMA CAR-T cellmurine BCMA CAR-T cell
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on murine BCMA-CART.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on murine BCMA-CART.